Skip to main content

ADVERTISEMENT

Jason T. Bradley, MD

08/01/2008
Percutaneous femoral access is utilized for 7.5 million patients per year worldwide and vascular closure devices are used in approximately 2 million patients annually. All current vascular closure devices (VCDs) have been associated with...
Percutaneous femoral access is utilized for 7.5 million patients per year worldwide and vascular closure devices are used in approximately 2 million patients annually. All current vascular closure devices (VCDs) have been associated with...
Percutaneous femoral access is...
08/01/2008
Journal of Invasive Cardiology
Case Report
08/01/2008
J INVASIVE CARDIOL 2007;19:E99-E101 Stent fracture has been reported with the Cypher™ sirolimus-eluting stent (Cordis Corp., Miami, Florida) in 4 patients since the introduction of drug-eluting stents in 2004.1,2 In all of these cases, the...
J INVASIVE CARDIOL 2007;19:E99-E101 Stent fracture has been reported with the Cypher™ sirolimus-eluting stent (Cordis Corp., Miami, Florida) in 4 patients since the introduction of drug-eluting stents in 2004.1,2 In all of these cases, the...
J INVASIVE CARDIOL...
08/01/2008
Journal of Invasive Cardiology
Cath Lab Management
10/06/2008
Abstract Background. Vascular closure devices (VCDs) improve patient comfort and decrease time to ambulation. However, VCD studies have excluded patients with high-risk femoral artery anatomy; we examined the safety and efficacy of...
Abstract Background. Vascular closure devices (VCDs) improve patient comfort and decrease time to ambulation. However, VCD studies have excluded patients with high-risk femoral artery anatomy; we examined the safety and efficacy of...
Abstract Background. Vascular...
10/06/2008
Cath Lab Digest